Cellular Senescence and Organismal Aging
========================================

Aging is the result of a gradual functional decline at the cellular, and ultimately, organismal level, resulting in the development of myriad chronic illnesses including heart disease, stroke and diabetes. On a cellular level, aging was first described by [@B74], who demonstrated that somatic mammalian cells have a finite propensity for cell division, after which they enter an irreversible growth arrest termed cellular senescence. Senescent cells are characterized by their inability to proliferate, resistance to apoptosis, and secretion of factors that promote inflammation and tissue deterioration ([@B23]; [@B103]; [@B75]). The molecular basis underlying Hayflick's observations came to light only decades later. In the early 1970s, Watson and Olovnikov proposed that during semi-conservative DNA replication of linear chromosomes, the removal of the terminal RNA primer, required to initiate lagging strand synthesis, would result in a gap that can no longer be filled by conventional DNA polymerases. As a result of this "end replication problem\", chromosome terminal sequences, termed telomeres ([@B19]) shorten during each replication cycle ([@B74]; [@B187]; [@B136]; [@B2]). Critically shortened telomeres trigger a persistent activation of DNA damage response (DDR) pathways, thereby resulting in cellular senescence ([@B42]). It is now clear that several types of cellular stressors can trigger senescence. These include telomere shortening and dysfunction ([@B42]; [@B171]), inadvertent activation of oncogenes, termed oncogene-induced senescence (OIS) ([@B157]; [@B120]; [@B170]), changes in chromatin structure and epigenetic stress ([@B8]; [@B127]), oxidative stress, mitochondrial dysfunction ([@B190]), or persistent activation of DNA damage checkpoints ([@B42]; [@B152]). There is increasing evidence suggesting that senescent cells accumulate in aging tissues and organs, thereby impairing physiological processes, including regeneration, and contributing to organismal aging ([@B53]; [@B98]; [@B89]).

Senescence Biomarkers
=====================

The identification of unique markers that unequivocally detect and quantify senescent cells, particularly *in vivo*, remains challenging ([@B160]). Senescent cells display an enlarged and flattened cell shape ([@B73]; [@B28], [@B29]), and elevated senescence-associated β-galactosidase (SA-β-gal) activity, which remains the gold standard to identify senescent cells in culture and tissue samples ([@B53]; [@B48]). However, this assay requires active enzymatic SA-β-gal activity, which is retained in fresh tissue samples but often lost in fixed or cryopreserved tissues ([@B158]; [@B107]). In addition, non-specific SA-β-gal activity can be detected in early passage adult melanocytes proliferating in culture, in hair follicles, sebaceous glands, and eccrine glands and ducts in both young and old human skin ([@B53]), as well as in proliferating surface luminal cells of the duodenum ([@B65]). Importantly, it remains difficult to multiplex the conventional detection method for SA-β-gal with other senescence-associated or cell-type specific markers, hence limiting the ability to identify senescent cell types or populations within a complex tissue or organ. Toward this goal, a modified flow cytometry-based method of multiplexing SA-β-gal with other senescence markers has been reported ([@B17]). However, such multiplexing strategies involving SA-β-gal in tissue biopsies *in situ* remains laborious. Despite being a hallmark of senescent cells, SA-β-gal activity does not play a mechanistic role in triggering senescence: cells from patients with autosomal recessive G(M1)-gangliosidosis lack lysosomal β-gal activity, but retain their ability to senesce ([@B107]).

As senescent cells are terminally growth arrested, cell cycle regulators such as p16^INK4a^, p21^CIP1^ and p53 ([@B34]) are commonly employed to detect senescent cells. p16^INK4a^, p21^CIP1^ and p53 were simultaneously upregulated in human skin fibroblasts post-ultraviolet (UV) radiation ([@B29]). p16^INK4a^ plays a key role in cell cycle control upstream of the retinoblastoma tumor suppressor protein, and p16^INK4a^-positive senescent cells accumulate in an age-dependent manner in multiple tissues including the skin ([@B203]; [@B98]; [@B120]; [@B76]; [@B150]; [@B39]; [@B184]). p16^INK4a^-positive cells accumulate in preneoplastic lesions, including melanocyte-rich benign human nevi, caused by activating mutations in N-RAS or its downstream target BRAF ([@B120]; [@B87]). Considering the role of p16^INK4a^ in mediating senescence, it is not surprising that this locus is frequently mutated in a variety of human cancers, including skin epithelial tumors ([@B167]; [@B46]).

Although less well understood, senescence is also characterized by widespread chromatin remodeling. Normal cellular aging is associated with global heterochromatin loss, characterized by markers H3K9me3 and H3K27me3 ([@B175]). In agreement with these findings, cells from patients with the accelerated aging syndrome Hutchinson--Gilford progeria syndrome (HGPS) exhibit a profound loss of heterochromatin ([@B122]; [@B163]; [@B30]). Predominantly during OIS *in vitro*, heterochromatin is redistributed into 30--50 punctate DNA-dense senescence-associated heterochromatin foci (SAHF). SAHF are silent domains that co-localize with H3K9me3 and heterochromatin protein 1 (HP1) and may lock cells in a senescent state by transcriptionally repressing genes involved in cell proliferation ([@B130]; [@B154]; [@B159]). In contrast, SAHF formation was not observed in HGPS patient cells or preneoplastic lesions that express other senescence markers ([@B155]; [@B163]; [@B97]; [@B87]). Long-term monitoring of senescent cells *in vitro* revealed progressive proteolysis of Histones 3 and 4 without DNA loss. Reduced histone content was also observed in nevus melanocytes, as compared to neighboring non-senescent melanocytes and keratinocytes *in vivo* ([@B87]). These studies confirm the dramatic structural changes of chromatin in senescent cells. In addition, the same authors also noted the presence of cytoplasmic chromatin fragments (CCFs) in ∼20% of cells undergoing replicative senescence (RS) or OIS *in vitro*. CCFs were positive for H3K9me3 and γ-H2A-X, but negative for 53BP1 and lamin A/C, and targeted for degradation by autophagy. The accumulation of such chromatin fragments within the cytoplasm suggests that the integrity of the nuclear envelope becomes compromised in senescent cells ([@B87]).

Indeed, the nuclear lamina, a proteinaceous network that lies beneath the inner nuclear membrane, undergoes dramatic remodeling during cellular senescence ([@B162]; [@B61]; [@B56]). Lamin B1, an intermediate filament protein expressed in all somatic cells ([@B168]; [@B79]), is downregulated in cells undergoing RS, OIS and UV-induced senescence *in vitro* ([@B162]; [@B61]; [@B56]; [@B87]; [@B154]; [@B159]; [@B186]). Lamin B1 levels also decline during chronological aging of human skin *in vivo* ([@B56],[@B57]), in senescent melanocytes within human nevi ([@B87]), in UV-exposed mouse skin epidermis ([@B186]), irradiated mouse liver ([@B61]) and in kidneys of a premature aging mouse model ([@B3]). Importantly, by co-staining with cell-type specific markers, lamin B1 staining facilitated the identification and quantification of senescent melanocytes within nevi as compared to neighboring keratinocytes within the epidermis ([@B87]). Similarly, co-staining lamin B1 with a keratinocyte differentiation marker followed by single cell analysis enabled us to quantify the accumulation and clearance of senescent cells in different epidermal compartments after UV exposure and upon regeneration, respectively ([@B186]). In addition to lamin B1, the inner nuclear membrane protein lamin B receptor (LBR) and the lamina-associated polypeptide-α (LAP2α) are also downregulated in senescent cells ([@B56]; [@B87]; [@B114]). However, LBR levels vary within the different epidermal layers in mouse skin, indicating that its expression may be altered during keratinocyte differentiation ([@B166]). Hence, this may limit the usage of LBR as an adequate senescence marker in human skin. Moreover, loss of LAP2α is not specific to senescent cells and also occurs in quiescent cells ([@B141]; [@B56]). Thus, co-staining of lamin B1 and LAP2α distinguishes senescent from quiescent cells ([@B56]). The mechanism of senescence-induced lamin B1 downregulation has been elucidated in detail by several groups. *LMNB1* transcription is decreased ([@B162]; [@B61]; [@B56]) and *LMNB1* mRNA is destabilized, possibly via targeted degradation by miR-23a ([@B111]; [@B56]). Additionally, lamin B1 protein is shuttled to the cytoplasm and degraded via autophagy ([@B55]). It should be noted that *LMNB1* mRNA levels alone are not a reliable indicator of senescence. For instance, *LMNB1* mRNA levels decrease in contact-inhibited quiescent fibroblasts, whereas lamin B1 protein levels remain stable as cells do not turn over ([@B56]). Taken together, although the mechanistic role of lamin B1 during cellular senescence is not fully understood, loss of lamin B1 is emerging as a potentially important biomarker to identify and quantify senescent cells *in vitro* and *in vivo*.

Concomitant with senescence-associated loss in chromatin organization, overall DNA methylation and expression of the DNA methyl-transferase DNMT1 decrease during cellular aging. These altered DNA methylation signatures can distinguish cells based on their developmental potential and may be used to predict chronological and biological age ([@B81]; [@B147]). Such distinct methylation patterns are also associated with chronologically aged and photoaged skin ([@B70]).

Persistent DNA damage is a critical trigger of cellular senescence and can be identified by the presence of γ-H2A-X and 53BP1 foci ([@B42]) and activated ataxia-telangiectasia mutated (ATM) kinase ([@B204]). However, while DNA damage *per se*, is not a marker for cellular senescence, the occurrence of telomere-associated DNA damage foci (TAF) has been used to detect senescent cells and quantify tissue aging ([@B76]; [@B89]; [@B77]; [@B183]). Replicative senescent baboon skin fibroblasts and skin biopsies from aged baboons displayed high incidence of TAF as indicated by co-localization of 53BP1 and γ-H2A-X on telomeric DNA ([@B76]; [@B89]). In agreement with these findings, shortened telomeres have been detected in skin from aged individuals, in sun-exposed skin and premalignant skin lesions including actinic keratosis (AK) ([@B169]; [@B85]). Other age-related genomic changes occur in mitochondrial DNA (mtDNA): age-dependent increase of mtDNA mutations and a common 4977 bp mtDNA deletion have been reported in several human tissues and cell types ([@B140]; [@B190]), as well as in photoaged human skin ([@B15]; [@B95]). Lastly, a histone variant H2A.J accumulates in an age-dependent manner in mouse and human skin, and in irradiated mouse skin. Both H2A.J and p16^INK4a^ levels were elevated in carcinogen-induced preneoplastic lesions but decreased in more advanced papillomas in mouse skin. H2A.J upregulation promotes expression of inflammatory genes, further exacerbating the senescence-induced hyperinflammation ([@B35]).

For long, senescent cells were considered passive bystanders that ceased to proliferate. Research in the past decade revealed that senescence can dramatically change cell function. For instance, senescent cells modulate their environment by secreting inflammatory cytokines, chemokines, matrix metalloproteinases (MMPs) and growth factors, collectively known as the senescence-associated secretory phenotype (SASP) ([@B1]; [@B37]; [@B104]; [@B152]) or senescence-messaging secretome (SMS) ([@B105]). As such, the presence of MMPs (e.g., MMP3 and MMP9), chemokines (e.g., CXCR2), cytokines (e.g., IL-6 and IL-8) ([@B1]; [@B104]) and insulin-like growth factor binding protein 7 (IGFBP7) ([@B185]) has been used as markers for senescent dermal fibroblasts and melanocytes *in vitro*. *In vivo*, elevated IL-6 has been detected in nevi melanocytes ([@B63]) while MMPs are detected in chronologically aged and photoaged skin, and are responsible for breakdown of the extracellular matrix (ECM) ([@B146]; [@B145]). In addition, the plasminogen activator inhibitor type 1 (PAI-1), an inhibitor of serine proteases, is elevated in dermal fibroblasts derived from patients with the premature aging syndromes HGPS and Werner ([@B128]; [@B66]; [@B30]), chronologically aged donors ([@B66]), and in tissues of premature aging BubR1 mutant mice ([@B6], [@B7]). PAI-1 plays a role in triggering senescence downstream of p53 ([@B96]) and is both a mediator and marker of senescence. Interestingly, most studies focused on fibroblasts *in vitro* and it remains to be determined whether the secretome of other senescent cell types differs -- and how this may affect the function of neighboring cells. It is noteworthy that expression of p53 or p16^INK4a^ alone may not be sufficient to trigger a SASP as a persistent DDR is mandatory ([@B152]; [@B39]).

High mobility group box-1 (HMGB1) belongs to the family of alarmins, which is an inflammatory mediator important in tissue damage signaling ([@B16]; [@B196]). In senescent cells, HMGB1 translocates from the nucleus to the cytoplasm and extracellular space, facilitating the release of SASP factors including IL-1β, IL-6 and MMP3 ([@B43]; [@B17]). UVB-exposure stimulated the release of HMGB1, IL-1 and IL-6 in human keratinocytes *in vitro*, and reduced nuclear Hmgb1 expression in mouse skin epidermis *in vivo* ([@B90]). Although HMGB1 is used as a marker to detect senescent cells in various contexts ([@B43]; [@B190]; [@B17]), its utility to detect senescent cells in human skin remains to be investigated.

Taken together, various senescence markers are currently being used individually and in combination, in different biological contexts *in vitro* and *in vivo* (**Figure [1](#F1){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). Nevertheless, further characterization of current markers and the identification of additional markers are indispensable to reliably detect and quantify senescent cells *in vitro* and *in vivo*. In particular, it is essential to develop better methods to multiplex senescence markers with other cell-type specific markers to identify and quantify senescent cell types in multi-compartment organs such as the skin and its appendages including sebaceous glands and hair follicles. Here, we will focus on what is known about the accumulation of senescent cells in skin, how they may affect skin function and contribute to age-related skin pathologies.

![Schematic representation of young and aged human skin. **(Top)** Illustration of young **(Left)** and aged senescent cells **(Right)**. Senescent cells are characterized by (1) enlarged and flattened cell morphology, (2) increased senescence-associated β-galactosidase (SA-β-gal) activity, (3) p16 upregulation, (4) reduced lamin B1 expression, (5) translocation of nuclear HMGB1 into the cytoplasm and extracellular space and (6) secretion of senescence-associated secretory phenotype (SASP) factors, including inflammatory cytokines and metalloproteinases. **(Bottom)** The epidermis consists of keratinocytes, arranged into basal (gray), spinous, granular and cornified layers. Keratinocytes progressively flatten as they move apically and lose their nuclei. Melanocytes (brown) reside within the basal layer; their dendrites branch to neighboring keratinocytes to facilitate pigment transfer. The dermal-epidermal junction (DEJ) separates the epidermis from the underlying dermis. Dermal fibroblasts (blue) reside among collagen and elastin fibers (green fibers) in the dermis. Aged skin **(Right)** becomes atrophic due to reduced proliferation, exhibits abnormal pigmentation, increased inflammation and breakdown of collagen fibers.](fgene-09-00247-g001){#F1}
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Biomarkers previously described in skin aging.

  Biomarkers                               *In vitro*                                                                                                                                                               *In vivo*                                                                                                                                              Reference
  ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------
  SA-β-gal                                 RS fibroblasts, keratinocytes, melanocytes (*Hu*), UVI keratinocytes and fibroblasts (*Hu*)                                                                              CA epidermis (*Hu*) UVI epidermis (*Ms*)                                                                                                               [@B53] [@B29]; [@B186]
  Enlarged, flattened cell morphology      RS fibroblasts (*Hu, Bb*), UVI keratinocytes and fibroblasts (*Hu*)                                                                                                      Not well documented                                                                                                                                    [@B74]; [@B28], [@B29]; [@B89]; [@B186]
  p16^INK4a^                               OIS melanocytes (*Hu*), RS fibroblasts (*Bb*) and ROT-treated fibroblasts (*Hu*)                                                                                         Nevi melanocytes (*Hu*), premalignant papillomas (*Ms*), CA skin (*Bb*), CA epidermis, dermis and hair follicles (*Hu*)                                [@B33]; [@B120]; [@B76]; [@B150]; [@B89]; [@B184], [@B183]; [@B87]
  Lamin B1                                 UVI keratinocytes (*Hu*) and OIS melanocytes (*Hu*)                                                                                                                      CA epidermis (*Hu*), nevi melanocytes (*Hu*) and UVI epidermis (*Ms*)                                                                                  [@B56],[@B57]; [@B87]; [@B186]
  SASP (cytokines, MMPs, growth factors)   OIS melanocytes (IL-1, IL-6, IL8, IGFBP7; *Hu*), CA fibroblasts (IL-6, IL-8; *Hu*), UVI keratinocytes (IL-1, IL-6, HMGB1; *Hu*), HGPS and WS fibroblasts (PAI-1; *Hu*)   CA and UVI epidermis (MMPs, *Hu*), UVI skin (Hmgb1; *Ms*), nevi melanocytes (IL-6; *Hu*), and DNA damaged fibroblasts (IL-6, IL-8, Mmp1, Mmp3; *Ms*)   [@B128]; [@B66]; [@B37]; [@B104]; [@B185]; [@B91]; [@B90]; [@B30]; [@B145]; [@B63]
  Telomere-associated foci (TAFs)          RS fibroblasts (*Bb*) and ROT-treated fibroblasts (*Hu*)                                                                                                                 CA skin (*Bb*)                                                                                                                                         [@B76]; [@B89]; [@B183]
  mtDNA modification                       UVI keratinocytes (*Hu*)                                                                                                                                                 UVI skin (*Hu*)                                                                                                                                        [@B15]; [@B95]
  Chromatin modification                   HGPS fibroblasts (H3K27me3; *Hu*) and OIS melanocytes (CCFs, H3, H4; *Hu*)                                                                                               Nevi melanocytes (H3; *Hu*), CA skin (H2A.J; *Ms, Hu*), UVI and premalignant lesions (H2A.J; *Ms*)                                                     [@B87]; [@B30]; [@B35]
                                                                                                                                                                                                                                                                                                                                                                           

Hu, human; Ms, mouse; Bb, baboon; SA-β-gal, senescence-associated β-galactosidase; UVI, ultraviolet irradiated; RS, replicative senescent; OIS, oncogene-induced senescent; ROT, rotenone; CA, chronologically aged; SASP, senescence-associated secretory phenotype; MMPs, matrix metalloproteinases; mtDNA, mitochondria DNA; CCFs, cytoplasmic chromatin fragments; H3, histone 3; H4, histone 4.

Skin Aging
==========

Skin is the largest organ of the human body: it provides a barrier against harmful organisms and substances, protects against UV radiation and regulates water loss and body temperature ([@B20]). The skin is a complex organ, consisting of several compartments with different functions. The outermost epidermis is stratified into four sublayers (basal, spinous, granular and cornified layer) with keratinocytes being the predominant cell type. Pigment-producing melanocytes reside within the basal layer of the epidermis, determine skin color and possess photo-protecting properties (**Figure [1](#F1){ref-type="fig"}**). The dermal-epidermal junction (DEJ) connects the epidermis to the underlying dermis, which harbors dermal fibroblasts and appendages such as hair follicles, sebaceous glands, and sweat glands.

Skin aging is a multi-factorial process that affects nearly every aspect of its biology and function; it is driven by both intrinsic (e.g., time, genetic factors, hormones) and extrinsic (e.g., UV exposure, pollution) factors. Characteristics of intrinsic or chronological aging include visible signs such as thin and dry skin, fine wrinkles, decreased elasticity, aberrant pigmentation, hair graying and hair loss. Epidermal thinning is, in part, caused by decreased proliferation and renewal capacity of basal keratinocytes and reduced epidermal stem cell number ([@B94]; [@B124]; [@B121]; [@B56]; [@B113]). Besides the epidermis, both the DEJ and dermis also become thinner ([@B106]). Fibroblasts residing within the dermis generate an ECM that provides the skin with structural integrity and elasticity. During aging, the ECM undergoes structural alterations and degradation (**Figure [1](#F1){ref-type="fig"}**), thought to result in dermal thinning, increased wrinkling and loss of elasticity ([@B164]). Although the number of senescent cells increases during chronological aging of human skin ([@B53]; [@B150]; [@B184]; [@B56]; [@B63]), a more detailed characterization as to which cell types or skin compartment undergoes senescence is necessary.

UV and Skin Aging
=================

In addition to chronological aging, extrinsic factors including exposure to sunlight, pollutants and cigarette smoke can accelerate skin aging. While most UVC is blocked by the ozone layer, UVA and UVB rays reach the earth's surface and contribute to skin aging and cancer development. UVA is a weak mutagen, yet penetrates into the dermis contributing to oxidative stress and tissue inflammation. UVB is more mutagenic as it directly interacts with DNA to generate dipyrimidine photoproducts, resulting in DNA damage during DNA replication ([@B148]; [@B198]). Acute UV radiation results in sunburns, aberrant pigmentation and immune suppression, whilst chronic exposure is associated with premature skin aging and a predisposition to develop malignancies ([@B45]; [@B84]; [@B146]; [@B12]; [@B151]). Sun-exposed skin appears thick and rough, marked with coarse wrinkles, visible appearance of blood vessels under the skin surface (telangiectasia) and aberrant pigmentation ([@B115]; [@B191]). A key histological hallmark of photodamaged skin is the accumulation of amorphous elastic fibers (solar elastosis), accompanied by fragmented and disorganized collagen in the dermis ([@B179], [@B178]; [@B146]; [@B188]). Solar elastosis may be a consequence of impaired elastic and fibrillin production, elevated breakdown by MMPs secreted by senescent cells, or a direct consequence of UV exposure ([@B161]; [@B145]; [@B142]). *In vitro*, UVB-exposed skin cell types (fibroblasts, keratinocytes) exhibit DNA damage, cell cycle arrest and express senescence biomarkers such as increased SA-β-gal activity, p16^INK4a^, p21^CIP1^, p53 activation and lamin B1 downregulation ([@B25]; [@B47]; [@B110]; [@B117]; [@B186]). *In vivo*, chronic low dose exposure to UVB resulted in accumulation of DNA damage and lamin B1-low senescent cells within the mouse epidermis, but not the dermis ([@B186]), a reduction in stem cell numbers in the hair follicle, and p21^CIP1^ accumulation in epidermis and hair follicle stem cell region ([@B117]).

Although the number of melanocytes in our skin decreases and skin color in sun-protected areas lightens with age ([@B64]; [@B138]), aberrant pigmentation (hyper- and hypopigmentation; i.e., sun spots and freckles) occurs at chronically sun-exposed body parts ([@B138]; [@B31]). Interestingly, in a 3D organotypic skin model comprised of keratinocytes, melanocytes and fibroblasts, the presence of aged fibroblasts resulted in increased melanogenic gene transcription, increased epidermal melanin and hyperpigmentation ([@B59]). Diverse pigmentary changes occur in aged skin and future studies will investigate whether senescent cell types accumulate at these lesions and how they may affect pigmentation. We anticipate that multiplexing senescence markers with cell-type specific markers will shed light as to how chronological aging and/or UV exposure modulate the complex interplay between pigment-producing melanocytes and their neighboring epidermal keratinocytes and dermal fibroblasts.

Pollution and Skin Aging
========================

More recently, it has been shown that air pollution contributes to various aspects of skin aging. Residents living near highly polluted areas and exposed to high levels of traffic-related particles and nitrogen dioxide developed pigmentary changes and increased coarse wrinkles ([@B181]; [@B82]). Similarly, exposure to tobacco smoke accelerates skin aging, resulting in increased wrinkling, elastosis, telangiectasia and laxity in the skin ([@B156]; [@B125]; [@B181]). Application of tobacco extracts to skin and oral fibroblasts *in vitro* triggered several hallmarks of senescence including premature cell cycle arrest, oxidative DNA damage, secretion of inflammatory cytokines and MMPs, and downregulation of cell junction proteins E-cadherin and ZO-1 ([@B36]). The ability to detect and quantify senescent cells in aged skin is indispensable to further elucidate how pollution may accelerate senescence and how this in turn alters skin appearance and function.

Whilst aging results in dry, itchy and more irritable skin, the underlying cause is likely multifactorial and involves changes in skin barrier function, androgen levels and sebaceous gland function ([@B94]; [@B205]). Sebaceous glands contribute to skin oiliness and moisture by secreting a complex mix of lipids called sebum. While the number of sebaceous glands does not change during aging, its activity drastically decreases in postmenopausal females and males over 80 years old. Somewhat counterintuitive, contrasting its declining function and sebum production, the size of the sebaceous gland increases with age ([@B143]; [@B205]). Chronic UV exposure has also been implicated in sebaceous hyperplasia and carcinoma ([@B108]; [@B72]). The specific involvement of cellular senescence in aging of the pigmentary units and sebaceous glands remains to be explored in greater detail.

Genetic Diseases and Skin Aging
===============================

Multiple genetic syndromes that result in persistent DNA damage or telomere dysfunction (telomeropathies) and cellular senescence, predispose the skin to accelerated aging and/or carcinogenesis ([@B71]; [@B44]; [@B137]). HGPS is a rare early-onset premature aging syndrome caused by a mutation in lamin A, resulting in a truncated mutant protein termed progerin. HGPS patients exhibit signs of accelerated aging at 12--18 months after birth and die in their mid-teens as a result of cardiovascular complications. Early clinical signs include alopecia, sclerotic skin, loss of subcutaneous fat and aberrant skin pigmentation ([@B119]). At the cellular level, progerin expression results in atypical nuclear architecture, heterochromatin loss, DNA damage and premature senescence ([@B58]; [@B180]; [@B100]). The primary driver mechanisms of these complex cellular phenotypes remain unclear. Progerin sequestration of NRF2, a major factor in a cell's response to oxidative stress, has been suggested to play a role in progerin-dependent heterochromatin loss and DNA damage ([@B101]). Other studies linked progerin-induced DNA damage to replication defects ([@B78]; [@B189]) and telomere dysfunction ([@B102]; [@B49]; [@B13]; [@B30]; [@B192]).

Mandibuloacral dysplasia (MAD) and restrictive dermopathy (RD) are also caused by nuclear lamina aberrations. Similar to HGPS, MAD is caused by a lamin A mutation and patients exhibit growth retardation, skeletal abnormalities, skin atrophy and hyperpigmentation ([@B133]). RD is a rare neonatal lethal disease in which newborns exhibit intrauterine growth retardation, tight, erosive skin with hyperkeratosis, and sparse eyebrows and hair. RD is caused by loss of ZMPSTE24, a zinc metalloproteinase critical for the correct processing of lamin A ([@B131]). While RD does not reflect skin aging phenotypes *per se*, the occurrence of these skin-specific laminopathies highlights the importance of nuclear lamina functions in the development and homeostasis of skin and hair.

Werner syndrome (WS), also referred to as adult-onset progeria, is regarded as a milder form of progeria. WS patients start to exhibit clinical features including hair loss and graying, scleroderma-like skin, ulcers and osteoporosis in their 30's and die in their 50's due to myocardial infarction and cancer. WS has been linked to mutations in *WRN*, a member of the RecQ helicase family ([@B199]) that lead to defects in DNA replication, repair, and premature cellular senescence ([@B139]). Loss of function mutations in WRN result in defective telomere lagging strand synthesis, telomere loss and genomic instability ([@B41], [@B40]).

Bloom syndrome is another disorder caused by loss of function mutations in the RecQ DNA helicase and affects DNA replication and repair ([@B4]). Its clinical symptoms include the development of skin rash in sun-exposed areas, accelerated skin aging, alopecia, poikiloderma (irregular pigmentation, telangiectasia, and atrophy) and a predisposition to cancer ([@B68]; [@B62]).

Xeroderma pigmentosum (XP) is a rare autosomal recessive syndrome characterized by extreme sensitivity to sunlight, resulting in sunburn, aberrant pigmentation, dry skin, premature skin aging, and increased risk to develop skin malignancies, including squamous cell carcinoma (SCC), basal cell carcinoma (BCC) and melanoma ([@B22]). The median age of death for XP patients is 29--32 years and most frequently caused by metastatic skin cancers and neurodegeneration ([@B21]; [@B52]). The etiology of XP is characterized by defects in nucleotide excision repair (NER), a key pathway required to repair UVB-induced dipyrimidine photoproducts ([@B32]). Defects in NER lead to the accumulation of DNA damage, genomic instability, impaired cell growth, premature senescence and/or cell death ([@B132]; [@B18]). Similarly, two other disorders caused by NER defects are Cockayne syndrome and trichothiodystrophy (TTD); both diseases are characterized by premature aging, neurological abnormalities and skin photosensitivity. Additionally, TTD patients display rough skin and brittle hair ([@B86]; [@B172]).

Mutations in ATM, an important molecule involved in activating checkpoint signaling in response to DNA double strand breaks, cause Ataxia-telangiectasia, another rare early-onset neurodegenerative disease in which patients display skin abnormalities including vitiligo, hair graying and telangiectasia in sun-exposed skin ([@B204]; [@B51]; [@B153]).

Dyskeratosis congenita (DKC) is multi-systemic premature aging syndrome resulting in some skin defects. Initial clinical features appear during childhood and include abnormal skin pigmentation and nail dystrophy. During the second and third decade, patients develop bone marrow failure, ultimately resulting in their death. In addition, some patients exhibit an increased risk to develop premalignant and malignant lesions, including AK and SCC ([@B144]). DKC is caused by mutations in various components of telomerase (TCAP1, DKC1, TERC, TERT, NHP2, NOP10) or shelterin (TINF2), a protein complex involved in telomerase recruitment and telomere protection. These mutations result in impaired telomere maintenance, presumably in adult stem cell compartments, and premature telomere shortening ([@B123]; [@B11]; [@B54]).

A common feature of the abovementioned genetic syndromes is the accumulation of persistent DNA damage, either by impaired DNA replication, repair, or signaling, as well as by DNA damage at unrepairable loci such as telomeres, resulting in premature cellular senescence and accelerated skin aging ([@B24]). These phenotypes can be recapitulated in patient-derived fibroblasts, cell- or iPSC-based disease models and mouse models ([@B41], [@B40]; [@B112]; [@B11]; [@B200], [@B201]; [@B30]). However, the rarity of these genetic diseases coupled with limited access to tissue biopsies have hampered efforts to test whether senescent cells accumulate within patient tissues *in vivo*. How are these accelerated aging syndromes relevant to normal aging? During chronological aging, at least the accumulation of genomic alterations correlates with the onset of age-related phenotypes and diseases ([@B27]; [@B182]). Furthermore, an increase susceptibility to DNA damage ([@B193]) and decline in DNA repair capacity ([@B126]; [@B195]) have also been described in aging skin. Chronological aging can be accelerated by extrinsic factors that result in DNA damage, including UV radiation, particles from traffic pollution and cigarette smoke. In conclusion, increased DNA damage, impaired repair or signaling play a key conserved feature of premature aging syndromes and normal aging.

Role of Cellular Senescence in Wounds and Cancers
=================================================

Aging results in a progressive decline of skin function, leading to fragility, impaired barrier function, increased susceptibility to physical insults, infection, accumulation of age-related pathologies such as impaired wound healing and an increased risk of cancer ([@B109]; [@B116]).

Skin wound healing occurs in four stages: hemostasis, inflammation, proliferation and remodeling. Wound closure takes place during the proliferation phase and depends on the formation of granulation tissue and the generation of contractile myofibroblasts. A ground breaking study by [@B50] demonstrated that senescent cells transiently accumulate during the proliferative stage and secrete platelet-derived growth factor AA (PDGF-AA) to induce myofibroblasts differentiation and maturation, essential for wound closure. Elimination of senescent cells reduced the number of myofibroblasts, delayed wound closure and increased fibrosis, all of which could be prevented by ectopic administration of PDGF-AA ([@B91]; [@B50]). Similarly, senescent cells prevent fibrosis during liver regeneration ([@B99]; [@B92]). These results demonstrate that senescent cells play an important role in tissue repair via cell-autonomous mechanisms: in the skin through the secretion of PDGF-AA; in the regenerating liver by secreting Mmp9, Mmp13 and IL-6. Thus, senescent cells may limit tissue regeneration in order to protect against unrestricted cell proliferation. On the flip side, a prolonged presence of senescent cells in the elderly prevents re-epithelialization and wound closure resulting in chronic wounds ([@B80]; [@B118]; [@B176]; [@B173]; [@B177]). Taken together, cellular senescence plays a complex role during normal wound healing as well as in chronic wounds.

Senescence and Skin Cancer
==========================

Cellular senescence is a double-edged sword: on the one hand, the accumulation of senescent cells may contribute to various age-related complications; on the other hand, RS and OIS suppress uncontrolled proliferation of cells that are at risk for preneoplastic transformation, thereby limiting tumorigenesis. As a result, cells from premalignant clinical specimens of breast, colon, lung and bladder tumors exhibited persistent DNA damage checkpoint activation and expressed some senescence markers ([@B9], [@B10]; [@B67]; [@B134]; [@B170]). Besides promoting non-cell-autonomous growth inhibition, the production of SASP is also critical for the recruitment of immune cells that create an anti-tumorigenic microenvironment important for the clearance of senescent cells ([@B38]).

In the skin, the vast majority of benign nevi are caused either by activating mutations in N-RAS or BRAF, and are unlikely to progress toward melanoma. Melanocytes within these preneoplastic lesions are positive for multiple senescence markers, including SA-β-gal, p16^INK4a^ and loss of lamin B1 ([@B120]; [@B69]; [@B170]; [@B87]), which are absent in more advanced melanoma ([@B120]; [@B170]). Kras mutant mice also expressed increased senescence markers in premalignant lung and pancreatic adenomas, and in chemically induced skin papillomas ([@B33]).

Skin cancer represents the most common human cancer type and its incidence increases with age and UV exposure ([@B129]). Long-term exposure to sunlight results in persistent DNA damage, increased cellular senescence and formation of premalignant lesions such as AK. AK affects approximately 60% of individuals above the age of 40 with a history of sun exposure. If left untreated, a percentage of AK lesions will progress toward invasive SCCs ([@B14]; [@B165]). Clinically, 97% of SCCs are contiguous with AK ([@B83]) yet the risk of progression or regression remains difficult to assess. Although cells within AK lesions exhibit genomic instability and telomere shortening ([@B149]; [@B85]), it is unclear whether senescent cells accumulate within AK lesions. As senescent cells generally accumulate in premalignant, but not malignant lesions, the identification and quantification of senescent cells within AK lesions may serve as a valuable tool to diagnose and distinguish AK from SCC and predict the course of disease progression.

Senescent Cells: Therapeutic Opportunities for Cancer and Aging
===============================================================

Numerous studies have aimed at preventing the accumulation of senescent cells within aging tissues. However, strategies that involve blocking p16^INK4a^ and p53, or activating telomerase to extend the proliferative capacity of cells inevitably lead to an increased cancer risk. Thus, a safer approach might be to either selectively eliminate senescent cells from tissues or modulate their function (particularly the SASP). The use of a progeroid mouse model expressing a mutated form of the mitotic checkpoint BubR1 has proven instrumental in demonstrating that p16^INK4a^-positive senescent cells drive age-related pathologies, and that selective elimination of these cells can prevent or delay age-related tissue deterioration ([@B6], [@B7]). Similarly, clearance of p16^INK4a^-positive cells in normal-aging mice extended their median lifespan, delayed tumorigenesis, improved healthspan indices including heart and kidney function, and delayed age-related decline in exploratory behavior ([@B5]). Multiple recent studies confirmed that clearing senescent cells improved tissue function in various age-related pathologies including degenerative joint disease, hepatic fat accumulation and liver chemotoxicity ([@B194]; [@B3]; [@B60]; [@B88]; [@B135]). These studies established senescent cells as potential therapeutic targets in the treatment of aging and age-related diseases. As a result, compounds that selectively eliminate senescent cells (senolytics) are under investigation to treat and prevent various age-related diseases ([@B3]; [@B93]). While several molecular pathways that trigger senescence are under consideration for the development of senolytics, the majority are directed at the pathways that confer apoptosis-resistance in senescent cells (in particular the anti-apoptotic BCL protein family) ([@B26]; [@B197]; [@B202]). However, few studies have probed how treatment with senolytics may affect skin function and homeostasis. In one study involving a skin-specific keratin 5-driven *p14^ARF^* transgenic mouse model, senescent epidermal cells were efficiently eliminated upon delivery of ABT-737, a BCL-specific senolytic compound ([@B174]; [@B197]). Although elimination of senescent cells from the epidermis led to increased proliferation within hair follicles, the underlying mechanism or other consequences on skin function were not investigated. Thus, it remains to be determined whether senolytics offer novel therapeutic approaches to treat chronic wounds, skin inflammation, age-related pigmentation disorders and ECM breakdown, or whether their clearance would impair wound healing or other skin functions in younger individuals.

A prerequisite for any such studies is a better understanding as to which skin compartment or cell type becomes senescent in the myriad age-related skin pathologies. Multiplexing senescence biomarkers with cell-type specific markers will pave the way to address this question. In addition, it is important to better understand how senescence affects or modulates the function of various skin cell types. To date, most SASP studies have focused on dermal fibroblasts and little is known about the SASP of other skin resident cell types, including melanocytes, keratinocytes or cell types from skin appendages, such as sebocytes. This is particularly relevant in skin as the interplay between these different cell types is essential to regulate skin functions including pigmentation, barrier function, sebum production, wound healing and cancer progression.

Conclusion
==========

The recognition of the role of cellular senescence in tissue aging has progressed tremendously in the past decade and this is in part attributed to better characterization of senescence biomarkers which allows qualitative and quantitative detection of senescent cells *in vitro* and *in situ*. Recent studies provided evidence that senescent cells accumulate in aged skin and may be driving the functional deterioration that characterizes aging skin and age-related skin diseases. Improved methodologies to detect senescent cells and a better understanding how senescence affects cellular function will enable us to determine how they contribute to various age-related skin changes and pathologies, including impaired wound healing and tumorigenesis. Moreover, the careful evaluation of senolytics in animal models and 3D reconstructed skin organotypics will facilitate the successful translation of senolytics as a therapeutic intervention for skin aging. The accessibility of human skin offers advantages to test these hypotheses.
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